{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:01:51Z","timestamp":1777046511006,"version":"3.51.4"},"reference-count":23,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010585","name":"Osasun Saila, Eusko Jaurlaritzako","doi-asserted-by":"publisher","award":["2022222005"],"award-info":[{"award-number":["2022222005"]}],"id":[{"id":"10.13039\/501100010585","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biobizkaia","award":["IT BB\/I\/PMIR\/25\/003"],"award-info":[{"award-number":["IT BB\/I\/PMIR\/25\/003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,22]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Methylprednisolone pulses (MP) help achieve prolonged remission in patients with moderate\u2013severe systemic lupus erythematosus (SLE), but their potential effect in reducing damage accrual has not been addressed. This study aims to disclose whether MP given within the first year of follow-up could impact long-term damage accrual.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Observational study using clinical care data of patients included in the Lupus\u2013Cruces\u2013Bordeaux cohort, expanded with patients from the historic Lupus Cruces cohort, with a follow-up time \u22655 years and up to 10 years. The primary outcome was the presence of irreversible organ damage or death for any cause during the whole follow-up time; the early outcome was set at 5 years. In addition, specific SLE-related and GC-related, cardiovascular and other forms of damage were also assessed as outcomes. The effect of MP was evaluated by Kaplan-Meier survival curves and propensity score (PS)-adjusted Cox models, in the whole cohort and in groups of mild activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) &lt;6) and moderate\u2013severe activity (SLEDAI\u22656).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>469 patients were included, of whom 99 (21%) received MP. In the PS-adjusted Cox models, MP was associated with a significantly reduced risk for the primary outcome (adjusted HR 0.63, 95%\u2009CI 0.40 to 0.98, p=0.044), with the effect being significant also at 5 years (adjusted HR 0.61, 95%\u2009CI 0.37 to 0.98, p=0.042). The stratified analyses revealed that the benefit was restricted to the group of patients with moderate\/severe activity and mainly in lupus and glucocorticoid-related damage items.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study supports the role of the early MP in reducing long-term damage accrual and death, especially among patients with moderate\/severe activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006518","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:50:17Z","timestamp":1777042217000},"page":"e006518","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Early methylprednisolone pulses and prevention of long-term damage accrual in active systemic lupus erythematosus: a propensity score analysis of the Lupus\u2013Cruces\u2013Bordeaux cohort"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1007-5378","authenticated-orcid":false,"given":"Beatriz","family":"Mar\u00edn-Garc\u00eda","sequence":"first","affiliation":[{"name":"Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain"},{"name":"UPV\/EHU, University of the Basque Country, Leioa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-9353","authenticated-orcid":false,"given":"Luis","family":"Due\u00f1a-Bartolom\u00e9","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Paredes-Ruiz","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kima","family":"L\u00f3pez-Aldabe","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain"},{"name":"Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitario Galdakao-Usansolo, Usansolo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ortiz-de-Urbina","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain"},{"name":"Department of Internal Medicine, Hospital Universitario de Le\u00f3n, Le\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-7399","authenticated-orcid":false,"given":"Estibaliz","family":"L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, FHU ACRONIM, Haut-L\u00e9v\u00eaque Hospital, Bordeaux, France"},{"name":"UMR CNRS 5164, ImmunoConcEpT, Bordeaux University, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1043","authenticated-orcid":false,"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain"},{"name":"UPV\/EHU, University of the Basque Country, Leioa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026042407501376000_12.2.e006518.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171"},{"key":"2026042407501376000_12.2.e006518.2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.23322","article-title":"Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study","volume":"70","author":"Ruiz\u2010Arruza","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026042407501376000_12.2.e006518.3","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026042407501376000_12.2.e006518.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026042407501376000_12.2.e006518.5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/acr.25334","article-title":"Methylprednisolone pulses and prolonged remission in systemic lupus erythematosus: a propensity score analysis of the longitudinal Lupus-Cruces-Bordeaux inception cohort","volume":"76","author":"Ruiz\u2010Irastorza","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026042407501376000_12.2.e006518.6","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026042407501376000_12.2.e006518.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2026042407501376000_12.2.e006518.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00094112"},{"key":"2026042407501376000_12.2.e006518.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2026042407501376000_12.2.e006518.10","first-page":"288","article-title":"SLE disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026042407501376000_12.2.e006518.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.060"},{"key":"2026042407501376000_12.2.e006518.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.05.017"},{"key":"2026042407501376000_12.2.e006518.13","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.autrev.2019.102359","article-title":"Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts","volume":"18","author":"Ruiz-Irastorza","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026042407501376000_12.2.e006518.14","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12364"},{"key":"2026042407501376000_12.2.e006518.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew377"},{"key":"2026042407501376000_12.2.e006518.16","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026042407501376000_12.2.e006518.17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10067-023-06858-4","article-title":"Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: a post hoc analysis of COMOSLE-EGYPT study","volume":"43","author":"Sobhy","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026042407501376000_12.2.e006518.18","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the control arms of randomized controlled trials","volume":"76","author":"Figueroa\u2010Parra","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026042407501376000_12.2.e006518.19","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001562","article-title":"Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts","volume":"12","author":"Ruiz-Irastorza","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026042407501376000_12.2.e006518.20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/acr.24592","article-title":"Medium versus high initial prednisone dose for remission induction in lupus nephritis: a propensity score\u2013matched analysis","volume":"74","author":"Tselios","year":"2022","journal-title":"Arthritis Care & Research"},{"key":"2026042407501376000_12.2.e006518.21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026042407501376000_12.2.e006518.22","first-page":"880","article-title":"Prednisone and long-term damage in systemic lupus erythematosus: which is the threshold dose? A pilot study","volume":"31","author":"Danza","year":"2022","journal-title":"Lupus (Los Angel)"},{"key":"2026042407501376000_12.2.e006518.23","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:50:19Z","timestamp":1777042219000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006518"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006518","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}